Introduction
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microdeletions, translocations and intra/intergenic duplications [2, [5] [6] [7] . The SCN1A gene variants are listed on three webpages [8] [9] [10] . While gain-of-function mutations lead to increased neuronal excitability, loss-of-function mutations reduce the inhibitory action of GABAergic interneurons [11] . DS is a common form of EE and about 80% of DS patients have an SCN1A mutation approximately 90% of which arising de novo. DS is characterized by infantile onset, fever-sensitive, treatment resistant seizures and intellectual disability [12] . Seizure onset is in the first year of life, generally at around 6 months. At onset, seizures can be generalized or unilateral, clonic and tonic-clonic. During the course of the disease afebrile, myoclonic or focal seizures or atypical absences can also occur. Until seizure onset, development is normal. However, developmental delay and other neurological defects begin during the second year of life [1] . Despite the identification of many mutations in the SCN1A gene, the genotypeÀphenotype correlation is still not clear suggesting the involvement of either genetic or environmental modifiers in the development and progression of various diseases [13, 14] . Mutations causing truncation of the channel protein and missense mutations affecting voltage sensitivity and/or pore regions are more frequent in DS patients and missense mutations affecting channel function less severely are more frequent in GEFS+ [15] .
In order to initiate mutational screening of the SCN1A gene in Turkey and advance further our understanding of the relationship between the SCN1A sequence alterations and disease phenotypes such as GEFS+, DS and related epileptic encephalopathies, the conventional Sanger sequencing method and a modified strategy of massively parallel pyro-sequencing for rapid detection of mutations were established in this study.
Materials and methods

Subjects
Forty-six Turkish patients suspected to have DS, late-onset DS (LO-DS), unspecific EE (UEE) and GEFS+ were included in this study with the informed consent of their families. The study was conducted with the approval of the Institutional Review Board for Research with Human Subjects.
The study cohort consisted of DS (N = 30), LO-DS (N = 10), GEFS+ (N = 4) and UEE (N = 2) patients. DS was characterized by febrile or afebrile tonic or tonic-clonic seizures with onset within the first year of life and yielding developmental stagnation and regression onwards [16] . Patients with LO-DS had the same clinic with DS patients but disease onset was beyond the first year of age. GEFS+ was characterized with febrile seizures starting early in life that continued beyond the age of six, generally with a positive family history [17] . Two patients, due to the lack of complete clinical information did not fit into definitions of DS, LO-DS and GEFS+ but were also included since they had UEE characterized by absence seizures at onset and a degree of mental retardation later.
SCN1A gene amplification
Genomic DNA was extracted from K'EDTA-treated peripheral blood samples using MagNa Pure Compact Nucleic Acid Isolation Kit Large Volume (Roche Diagnostics, Mannheim, Germany).
All 26 exons including exon/intron boundaries of the SCN1A gene were amplified by polymerase chain reaction (PCR) in 36 separate reactions using previously reported primer pairs [18] . For massively parallel sequencing, all amplicons were fluorometrically quantified using Quant-iT-PicoGreen dsDNA assay Kit (Invitrogen, ABD) on Light Cycler 480 (LC480II, Roche Diagnostics, Mannheim, Germany). Amplification conditions are available upon request.
Sanger sequencing
Purified PCR products were Sanger sequenced at Macrogen, Seoul, Korea. All mutations were confirmed by repeated PCR and re-sequencing. Nucleotides were numbered according to reference sequences NM_001165964.1 and NP_001159436.1 where A of the ATG start codon corresponded to nucleotide number one. Bioinformatics tools namely, Mutation Taster [19] , Polyphen [20] and Provean [21] were used to evaluate the putative effects of novel mutations.
Massively parallel amplicon sequencing (MPAS)
SCN1A amplicons of each patient were pooled at equal molecule amounts and purified by MinElute DNA purification kit (Qiagen, ABD). Ten nucleotides long MID sequences specifying each patient were ligated to amplicons in each pool using GS Rapid Library Preperation Kit Lib-L (Roche, Germany) as described in the GS Junior Rapid Library Preparation Manual. Concentration of pooled amplicons was measured both by Quant-iT-PicoGreen dsDNA assay Kit (Invitrogen, ABD) and also by qPCR using KAPA NGS quantification kit (KAPA systems, ABD) on LightCycler 480II. Dilutions were made to have single fragment per bead and the sequencing library was prepared for emulsion PCR (emPCR) using GS Junior Titanium emPCR Kit Lib-L (Roche, Germany) as described in GS Junior emPCR Lib-L manual. DNA attached beads were picked up magnetically and pyrosequenced using GS Junior sequencing kit by following the instructions in the GS Junior sequencing method manual. Amplicon sequences were analyzed by Amplicon Variant Analyzer (AVA) program (Roche, Gernmany) using the SCN1A reference sequence, PCR primer and MID sequence information. In the result of AVA analysis, a variant list was obtained for each patient. The variants were filtered for known SNPs and unique variants were validated by Sanger sequencing.
Statistical analyses
Statistical analysis was conducted using SPSS software (Version 22) nonparametric tests module for Independent Samples KruskalÀWallis Test with 95% confidence interval.
Results
A total of 46 patients with DS, LO-DS, EE and GEFS+ phenotypes were analyzed for SCN1A sequence variations by Sanger sequencing (30 patients) and Massively Parallel Amplicon Sequencing (16 patients) methods. Out of 46 patients, 19 (41.3%) had a sequence variation in the SCN1A gene, 12 of which were novel. Genetic variations and clinical information of patients are given in Tables 1 and 2 , respectively. Among 30 patients with DS phenotype 12 had a mutation in the SCN1A gene (40%), on the other hand, only three out of 10 LO-DS patients were positive for SCN1A mutations (30%). Two of the four GEFS+ patients had a maternally inherited SCN1A mutation. Two UEE patients had a novel de novo frameshift mutation (2DS4) and a previously reported and paternally inherited variant (11DS23). This variant was present in the ExAC database with low frequency (0.0015).
Clinical summary of patients with SCN1A mutations
All patients except 11DS23, 29DS57 and 57DS121 had FS at disease onset (84%) and three patients had their first seizure after vaccination. All patients except 29DS57 had variable degrees of mental retardation with additional autistic features, speech delay and motor delay. Among DS patients, only 6DS12, 14DS26 and 15DS27 were pharmacoresistant (Table 1) . 
Summary of the genotype information
Out of 19 identified SCN1A mutations, 12 were missense, one was in-frame deletion and six were truncating mutations. Seven mutations were on the homology domains (one truncating and six missense), eight were on the linker domains (three truncating and five missense) and four were on either N-or C-Terminal domains (three missense and one in-frame deletion). Nine of the identified variants occurred de novo and three were inherited. Seven variants could not be tested for inheritance since parental samples were unavailable ( Table 2 and Fig. 1 ). The effect of 12 novel variants on protein function was assessed by in silico tools, Mutation Taster [19] , Polyphen [20] , SIFT [21] and all were predicted to be pathological.
Genotype/phenotype correlation
DS is characterized by febrile or afebrile seizures starting in the first year of life. In our cohort disease onset for SCN1A positive patients ranged from 10 days to 5 years. Twelve patients had disease onset within the first year of life and six patients had unusual disease onset beyond 2 years of age. Because of this discrepancy median onset was 8.5 months but mean onset was 19.3 months. Patients with a mutation (either truncating or missense) on the linker regions had significantly later disease onset than patients with mutations on the homology regions (Independent samples KruskalÀWallis test, p < 0.05). For instance, the DS patient 1DS1 with the earliest disease onset (10 days) had a missense mutation on the S4 transmembrane region (Voltage Sensor). In addition, while three DS patients with a mutation on the N-terminal cytoplasmic region had disease onset at around 5 months of age, two GEFS+ patients (55DS119 and 56DS120) with disease onset at 2 and 3 years of age, respectively, had a mutation on the C-terminal cytoplasmic region and on a linker region.
Regarding the inheritance of variants, three patients with remarkably late onset epilepsy (11DS23, 55DS119 and 56DS120) had an inherited mutation while the other three (24DS50, 34DS68 and 57DS121) could not be tested for inheritance due to unavailability of the parental samples.
It is known that, while DS patients more often have truncating mutations, patients with milder phenotypes like GEFS+ have missense mutations [10] . In our cohort, there were six truncating mutations in total. Out of these, three frameshift deletions and one splice acceptor mutation occurred in DS patients and one nonsense and one splice donor mutation were associated with LO-DS.
Clinical information of SCN1A negative patients
In our cohort of 27 SCN1A negative patients, 18 (67%) were diagnosed as DS, seven (26%) as LO-DS and two patients (7.4%) as GEFS+. Among the SCN1A negative patients, age of onset ranged from 1.5 to 72 months. While mean age of onset is 15 months, median is 6 months since 16/27 patients had disease onset within the first year of life. Though 13/27 patients had FS at seizure onset, ongoing seizures dominated by GTCS (10/30) in SCN1A negative patients. With regard to psychomotor functions, 92% (25/27) of SCN1A negative patients had a degree of psychomotor regression from learning disability to severe mental and motor retardation. Remarkably, two of the SCN1A negative patients had abnormal development before epilepsy. Six patients had ataxia or spasticity and one patient had gait problems (27DS53) that are comorbidities of DS.
Comparison of detection methods
In order to accelerate the mutational screening of the SCN1A gene, MPAS method was implemented. Gene regions and exon/ intron boundaries of the SCN1A gene were amplified for 12 patients and sequenced in a single GS Junior sequencer run (Roche, Germany). To compare the two approaches, two Sanger negative and two Sanger positive (one missense and one deletion) samples were also included in MPAS. The deletion in patient 14DS26 (c.4402-4406 delCAAGA) was confirmed (Fig. 2a) . However, the missense variation in patient 12DS24 was not observed by MPAS. Repeated Sanger sequencing showed that the initial result was a false positive. In the two Sanger sequencing negative patients, MPAS was also negative. In total, 16 patients were analyzed by MPAS, 6 variations in the SCN1A gene were detected and validated by Sanger sequencing without any false-positives. Fig. 2b shows MPAS and Sanger sequencing results of patient 54DS112.
Discussion
SCN1A is the most clinically relevant gene for a wide spectrum of epilepsy phenotypes and the search for a mutation in the SCN1A gene is the first widely accepted step in DNA diagnosis of patients Table 2 SCN1A genotypes of the patients (reference sequences NM_001165964.1 from cds start and NP_001159436.1, * denotes novel mutations that are not present in SCN1A database [10] suspected to have DS, GEFS+ and EE syndromes. It is reported that 80% of DS patients have an SCN1A mutation [12] , and there are several reports of SCN1A mutations in patients with different epilepsy syndromes, also in patients with migraine and autism [22] . This study also demonstrated that in a clinically heterogeneous cohort, although biased toward DS phenotype, 46% of the patients had epilepsy caused by SCN1A mutations and the mutation ratio among DS patients were 41.3% which is significantly lower than the reported ratio. This fact may stem from our less stringent inclusion criteria or unavailability of data on DNA aberrations like indels and microdeletion/duplications. Furthermore, the DS phenotype in SCN1A negative patients may have resulted from mutations in other genes such as PCDH19 [11] and CHD2 [23] that were not analyzed in these patients. In order to attribute a diagnostic value to SCN1A mutation screening, several researchers tried to make a prognosis based on SCN1A mutations. For instance, in a recent study by Zuberi et al. [15] , a statistical analysis on 819 SCN1A mutations with respect to the mutation type (missense or truncating), effect of missense mutation on protein structure (Graham Score, GS) and also location of the mutation on the protein was conducted. It was shown that truncating mutations resulted in earlier disease onset, same as high GS score missense mutations [15] . On the other hand, missense mutations on voltage (S4) and ion-pore regions were associated with DS phenotype rather than GEFS+ [10] . Although our cohort was not large, nevertheless, we observed that patients with a mutation (either truncating or missense) on linker regions had significantly later disease onset than patients with mutations in homology regions and inherited variants yielded to later disease onset and milder phenotype, in agreement with the above analysis.
Of all reported SCN1A mutations, 81.8% were novel [10] . However, in our cohort, this ratio was 63%. One splice site (c.602 + 1 G > A) and one missense mutation (C.530 G > A) mutation was reported in several DS patients phenotypically similar to patients 10DS22 and 26DS52, respectively. On the other hand, one nonsense variant (c.1837 C > T) and splice site mutation (c.4498-1 G > T) were reported in several DS patients but our patients had significantly later disease onset (6y and 4y, respectively). c.301 C > T variant was reported in DS patients with similar phenotype with patient 29DS57, though one previously reported patient [4] had later disease onset. Finally, c.1881 G > A variant was reported to be associated with DS or EE phenotypes, however, patient 56DS120 had a phenotype compatible with GEFS+ [10] . None of the variants identified in this study were present in public variant databases except the c.1625 G > A variant, which is present in ExAC database with a low frequency (0.0015). This previously reported variant was associated with JME [3] , ASD [24] , GEFS+ [25, 26] and Infantile Epilepsy [27] with variable penetrance. The mutation disrupts the predicted tyrosine kinase site in the cytoplasmic loop 1, thus rather than demolishing channel function, it may have a regulatory effect on channel activity yielding a milder phenotype.
SUDEP is one of the most important causes of mortality in patients with epilepsy [28, 29] and is more frequently reported in patients diagnosed with DS [30] . Patient 48DS1104 with a novel mutation (c.1696C > T) was deceased with definite sudden unexplained death in epilepsy (SUDEP) at the age of 20 following last of his habitual generalized tonic clonic seizures. SUDEP in this patient was supported with autopsy findings. The underlying mechanisms of SUDEP are still largely unknown and debated [31] . Therefore, reporting DS patients with SUDEP may help to predict which patients are at risk and to find relevant mechanisms for prevention [32, 33] .
Although SCN1A screening is important for epilepsy diagnosis, the large size of the gene renders Sanger sequencing cumbersome. The comparative analysis of Sanger and MPAS sequencing showed that MPAS, which is more rapid and cost-effective, could effectively replace conventional SCN1A screening methods.
The accumulating data on SCN1A mutations will provide better prognosis of epilepsy patients and will ultimately lead to personalized medicine. However, further analysis of parents and long-term follow up of patients are of great importance since they may shed light on the effect of mutations, on the onset and prognosis of the particular disease, elucidating genotypeÀphenotype relationships and providing better treatment options for patients.
